MTOR is a promising therapeutical target in a subpopulation of pancreatic adenocarcinoma

Cancer Letters

Volumn 346, Issue 2, 2014, Pages 309-317

  Utomo, Wesley K ^a   Narayanan, Vilvapathy ^a   Biermann, Katharina ^a   van Eijck, Casper H J ^a   Bruno, Marco J ^a   Peppelenbosch, Maikel P ^a   Braat, Henri ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Flow cytometry; MTOR; Pancreatic cancer; Personalized medicine; Rapamycin

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; S6 KINASE; ANTINEOPLASTIC ANTIBIOTIC; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; PANCREAS ADENOCARCINOMA; PANCREAS BIOPSY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; CARCINOMA, PANCREATIC DUCTAL; DRUG EFFECTS; ENZYMOLOGY; IMMUNOHISTOCHEMISTRY; METABOLISM; MOLECULARLY TARGETED THERAPY; PANCREATIC NEOPLASMS; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; AUTOPHAGY; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84896109439     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.01.014     Document Type: Article

References (45)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Oettle H., Post S., Neuhaus P., Gellert K., Langrehr J., Ridwelski K., Schramm H., Fahlke J., Zuelke C., Burkart C., Gutberlet K., Kettner E., Schmalenberg H., Weigang-Koehler K., Bechstein W.O., Niedergethmann M., Schmidt-Wolf I., Roll L., Doerken B., Riess H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007, 297:267-277.
3. Rudloff U., Maker A.V., Brennan M.F., Allen P.J. Randomized clinical trials in pancreatic adenocarcinoma. Surg. Oncol. Clin. N. Am. 2010, 19:115-150.
4. A.C.Society American Cancer Society. Cancer Facts & Figures 2012 2012, Atlanta, American Cancer Society.
5. Conroy T., Desseigne F., Ychou M., Bouche O., Guimbaud R., Becouarn Y., Adenis A., Raoul J.L., Gourgou-Bourgade S., de la Fouchardiere C., Bennouna J., Bachet J.B., Khemissa-Akouz F., Pere-Verge D., Delbaldo C., Assenat E., Chauffert B., Michel P., Montoto-Grillot C., Ducreux M. U. groupe tumeurs digestives of, P. intergroup, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011, 364:1817-1825.
6. Braat H., Bruno M., Kuipers E.J., Peppelenbosch M.P. Pancreatic cancer: promise for personalised medicine?. Cancer Lett. 2012, 318:1-8.
7. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
8. Ardito C.M., Gruner B.M., Takeuchi K.K., Lubeseder-Martellato C., Teichmann N., Mazur P.K., Delgiorno K.E., Carpenter E.S., Halbrook C.J., Hall J.C., Pal D., Briel T., Herner A., Trajkovic-Arsic M., Sipos B., Liou G.Y., Storz P., Murray N.R., Threadgill D.W., Sibilia M., Washington M.K., Wilson C.L., Schmid R.M., Raines E.W., Crawford H.C., Siveke J.T. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 2012, 22:304-317.
9. Kanda M., Matthaei H., Wu J., Hong S.M., Yu J., Borges M., Hruban R.H., Maitra A., Kinzler K., Vogelstein B., Goggins M. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 2012, 142. 730-733 e739.
10. van Heek N.T., Meeker A.K., Kern S.E., Yeo C.J., Lillemoe K.D., Cameron J.L., Offerhaus G.J., Hicks J.L., Wilentz R.E., Goggins M.G., De Marzo A.M., Hruban R.H., Maitra A. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am. J. Pathol. 2002, 161:1541-1547.
11. Kennedy A.L., Adams P.D., Morton J.P. Ras, PI3K/Akt and senescence: paradoxes provide clues for pancreatic cancer therapy. Small GTPases 2011, 2:264-267.
12. LoPiccolo J., Blumenthal G.M., Bernstein W.B., Dennis P.A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy 2008, 11:32-50.
13. Hofmann I., Weiss A., Elain G., Schwaederle M., Sterker D., Romanet V., Schmelzle T., Lai A., Brachmann S.M., Bentires-Alj M., Roberts T.M., Sellers W.R., Hofmann F., Maira S.M. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. PLoS ONE 2012, 7:e44146.
14. Garrido-Laguna I., Tan A.C., Uson M., Angenendt M., Ma W.W., Villaroel M.C., Zhao M., Rajeshkumar N.V., Jimeno A., Donehower R., Iacobuzio-Donahue C., Barrett M., Rudek M.A., Rubio-Viqueira B., Laheru D., Hidalgo M. Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br. J. Cancer 2010, 103:649-655.
15. Zaytseva Y.Y., Valentino J.D., Gulhati P., Evers B.M. MTOR inhibitors in cancer therapy. Cancer Lett. 2012, 319:1-7.
16. Zhou H., Luo Y., Huang S. Updates of mTOR inhibitors. Anti-Cancer Agents Med. Chem. 2010, 10:571-581.
17. Javle M.M., Shroff R.T., Xiong H., Varadhachary G.A., Fogelman D., Reddy S.A., Davis D., Zhang Y., Wolff R.A., Abbruzzese J.L. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer 2010, 10:368.
18. Takeuchi H., Kondo Y., Fujiwara K., Kanzawa T., Aoki H., Mills G.B., Kondo S. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res. 2005, 65:3336-3346.
19. Bellizzi A.M., Bloomston M., Zhou X.P., Iwenofu O.H., Frankel W.L. The mTOR pathway is frequently activated in pancreatic ductal adenocarcinoma and chronic pancreatitis. Appl. Immunohistochem. Mol. Morphol. 2010, 18:442-447.
20. Guertin D.A., Sabatini D.M. An expanding role for mTOR in cancer. Trends Mol. Med. 2005, 11:353-361.
21. Sarbassov D.D., Ali S.M., Kim D.H., Guertin D.A., Latek R.R., Erdjument-Bromage H., Tempst P., Sabatini D.M. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 2004, 14:1296-1302.
22. Chung J., Kuo C.J., Crabtree G.R., Blenis J. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70kd S6 protein kinases. Cell 1992, 69:1227-1236.
23. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., Markhard A.L., Sabatini D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 2006, 22:159-168.
24. Wolpin B.M., Hezel A.F., Abrams T., Blaszkowsky L.S., Meyerhardt J.A., Chan J.A., Enzinger P.C., Allen B., Clark J.W., Ryan D.P., Fuchs C.S. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J. Clin. Oncol. 2009, 27:193-198.
25. Li Y., Deuring J., Peppelenbosch M.P., Kuipers E.J., de Haar C., van der Woude C.J. IL-6-induced DNMT1 activity mediates SOCS3 promoter hypermethylation in ulcerative colitis-related colorectal cancer. Carcinogenesis 2012, 33:1889-1896.
26. Hornick J.L., Lauwers G.Y., Odze R.D. Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver. Am. J. Surg. Pathol. 2005, 29:381-389.
27. Missiaglia E., Dalai I., Barbi S., Beghelli S., Falconi M., della Peruta M., Piemonti L., Capurso G., Di Florio A., delle Fave G., Pederzoli P., Croce C.M., Scarpa A. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J. Clin. Oncol. 2010, 28:245-255.
28. Efeyan A., Sabatini D.M. MTOR and cancer: many loops in one pathway. Curr. Opin. Cell Biol. 2010, 22:169-176.
29. Yu K., Toral-Barza L., Shi C., Zhang W.G., Lucas J., Shor B., Kim J., Verheijen J., Curran K., Malwitz D.J., Cole D.C., Ellingboe J., Ayral-Kaloustian S., Mansour T.S., Gibbons J.J., Abraham R.T., Nowak P., Zask A. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 2009, 69:6232-6240.
30. Garcia-Echeverria C. Blocking the mTOR pathway: a drug discovery perspective. Biochem. Soc. Trans. 2011, 39:451-455.
31. Britschgi A., Andraos R., Brinkhaus H., Klebba I., Romanet V., Muller U., Murakami M., Radimerski T., Bentires-Alj M. JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell 2012, 22:796-811.
32. Fitzgerald P.J. Homogeneity and heterogeneity in pancreas cancer: presence of predominant and minor morphological types and implications. Int. J. Pancreatol. 1986, 1:91-94.
33. Kopp J.L., von Figura G., Mayes E., Liu F.F., Dubois C.L., Morris J.P.t., Pan F.C., Akiyama H., Wright C.V., Jensen K., Hebrok M., Sander M. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 22:737-750.
34. Dai Z.J., Gao J., Ma X.B., Kang H.F., Wang B.F., Lu W.F., Lin S., Wang X.J., Wu W.Y. Antitumor effects of rapamycin in pancreatic cancer cells by inducing apoptosis and autophagy. Int. J. Mol. Sci. 2012, 14:273-285.
35. Iwamaru A., Kondo Y., Iwado E., Aoki H., Fujiwara K., Yokoyama T., Mills G.B., Kondo S. Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene 2007, 26:1840-1851.
36. Yang S., Wang X., Contino G., Liesa M., Sahin E., Ying H., Bause A., Li Y., Stommel J.M., Dell'antonio G., Mautner J., Tonon G., Haigis M., Shirihai O.S., Doglioni C., Bardeesy N., Kimmelman A.C. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 2011, 25:717-729.
37. van Veelen W., Korsse S.E., van de Laar L., Peppelenbosch M.P. The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling. Oncogene 2011, 30:2289-2303.
38. Avizienyte E., Loukola A., Roth S., Hemminki A., Tarkkanen M., Salovaara R., Arola J., Butzow R., Husgafvel-Pursiainen K., Kokkola A., Jarvinen H., Aaltonen L.A. LKB1 somatic mutations in sporadic tumors. Am. J. Pathol. 1999, 154:677-681.
39. Su G.H., Hruban R.H., Bansal R.K., Bova G.S., Tang D.J., Shekher M.C., Westerman A.M., Entius M.M., Goggins M., Yeo C.J., Kern S.E. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am. J. Pathol. 1999, 154:1835-1840.
40. Klumpen H.J., Queiroz K.C., Spek C.A., van Noesel C.J., Brink H.C., de Leng W.W., de Wilde R.F., Mathus-Vliegen E.M., Offerhaus G.J., Alleman M.A., Westermann A.M., Richel D.J. MTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome. J. Clin. Oncol. 2011, 29:e150-e153.
41. Asano T., Yao Y., Zhu J., Li D., Abbruzzese J.L., Reddy S.A. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 2004, 23:8571-8580.
42. Yao J.C., Shah M.H., Ito T., Bohas C.L., Wolin E.M., Van Cutsem E., Hobday T.J., Okusaka T., Capdevila J., de Vries E.G., Tomassetti P., Pavel M.E., Hoosen S., Haas T., Lincy J., Lebwohl D., Oberg K. T.T.S.G. Rad001 in advanced neuroendocrine tumors, everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 2011, 364:514-523.
43. Baselga J., Campone M., Piccart M., Burris H.A., Rugo H.S., Sahmoud T., Noguchi S., Gnant M., Pritchard K.I., Lebrun F., Beck J.T., Ito Y., Yardley D., Deleu I., Perez A., Bachelot T., Vittori L., Xu Z., Mukhopadhyay P., Lebwohl D., Hortobagyi G.N. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 2012, 366:520-529.
44. Motzer R.J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., Grunwald V., Thompson J.A., Figlin R.A., Hollaender N., Urbanowitz G., Berg W.J., Kay A., Lebwohl D., Ravaud A., Group R.-S. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
45. von Wichert G., Jehle P.M., Hoeflich A., Koschnick S., Dralle H., Wolf E., Wiedenmann B., Boehm B.O., Adler G., Seufferlein T. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res. 2000, 60:4573-4581.